Clinical Trial Update: p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer [Phase 2]

View source ↗

Summary

This is an update on a Phase 2 clinical trial evaluating a p53 gene therapy for recurrent ovarian epithelial cancer, fallopian tube cancer, and primary peritone…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Epithelial Cancer
• Peritoneal Cancer

Drugs mentioned

• Gendicine (recombinant adenovirus p53 gene therapy)

Snippet

Sponsor: Shenzhen SiBiono GeneTech Co.,Ltd | Conditions: Ovarian Epithelial Cancer, Fallopian Tube Cancer | Phase 2 | Status: UNKNOWN